Mutual of America Capital Management LLC Takes $469,000 Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

Mutual of America Capital Management LLC purchased a new position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 20,064 shares of the biopharmaceutical company’s stock, valued at approximately $469,000.

Several other large investors have also bought and sold shares of the business. NBC Securities Inc. raised its position in shares of TG Therapeutics by 58.9% during the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 485 shares during the last quarter. Quarry LP increased its holdings in TG Therapeutics by 9.1% in the second quarter. Quarry LP now owns 6,003 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 503 shares during the last quarter. Private Advisor Group LLC increased its holdings in TG Therapeutics by 3.9% in the third quarter. Private Advisor Group LLC now owns 14,407 shares of the biopharmaceutical company’s stock valued at $337,000 after purchasing an additional 542 shares during the last quarter. Blue Trust Inc. boosted its holdings in TG Therapeutics by 127.3% during the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 849 shares during the last quarter. Finally, KBC Group NV boosted its holdings in TG Therapeutics by 30.5% during the third quarter. KBC Group NV now owns 4,675 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 1,092 shares during the last quarter. 58.58% of the stock is currently owned by institutional investors and hedge funds.

TG Therapeutics Price Performance

TGTX stock opened at $35.00 on Thursday. The stock has a market cap of $5.45 billion, a PE ratio of -342.57 and a beta of 2.19. The stock has a 50-day moving average price of $26.00 and a two-hundred day moving average price of $21.95. TG Therapeutics, Inc. has a 1 year low of $12.32 and a 1 year high of $36.84. The company has a current ratio of 4.59, a quick ratio of 3.91 and a debt-to-equity ratio of 1.27.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The firm had revenue of $83.90 million for the quarter, compared to the consensus estimate of $81.68 million. During the same quarter in the previous year, the business posted $0.73 earnings per share. The firm’s quarterly revenue was down 49.4% compared to the same quarter last year. Equities analysts forecast that TG Therapeutics, Inc. will post 0.17 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently weighed in on TGTX shares. TD Cowen began coverage on shares of TG Therapeutics in a research report on Tuesday, October 29th. They issued a “buy” rating and a $50.00 price target on the stock. HC Wainwright increased their target price on shares of TG Therapeutics from $49.00 to $55.00 and gave the stock a “buy” rating in a report on Tuesday, November 5th. JPMorgan Chase & Co. lifted their price target on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research report on Monday. B. Riley upped their price objective on shares of TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. Finally, The Goldman Sachs Group lifted their target price on TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $40.67.

Insider Transactions at TG Therapeutics

In related news, Director Sagar Lonial sold 5,000 shares of TG Therapeutics stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $30.44, for a total value of $152,200.00. Following the sale, the director now owns 100,195 shares of the company’s stock, valued at approximately $3,049,935.80. The trade was a 4.75 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.50% of the stock is currently owned by insiders.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.